Cheap Diabetes Pill Takes On Aging

White tablets spilling from a plastic bottle — Photo: anek jaikui / Shutterstock

A pill that costs pennies and sits in millions of medicine cabinets for diabetes is now being tested to see if it can slow aging itself.

Quick Take

Metformin, a decades-old diabetes drug, is the subject of TAME, a major trial studying whether it can delay age-related disease in older adults.
The trial enrolls about 3,000 people ages 65 to 79 and was built with input from federal regulators to seek a new kind of drug approval tied to aging.
Earlier human studies already show metformin shifting gene activity and health markers in older adults toward patterns seen in younger, healthier people.
Most of the strongest evidence so far comes from diabetics, so how well it applies to healthy older adults is still being worked out.

A Diabetes Pill Gets a Bigger Job

Metformin has treated type 2 diabetes since the 1990s. It lowers blood sugar and improves how the body handles insulin. But researchers noticed something else. Diabetics taking metformin sometimes lived longer and got fewer age-related diseases than people without diabetes at all. That odd pattern pushed scientists to ask a bigger question: could this cheap pill slow aging in everyone, not just diabetics?

That question led to TAME, short for Targeting Aging with Metformin. It is a placebo-controlled trial run at about 14 sites across the United States. Roughly 3,000 adults between 65 and 79 take either metformin or a dummy pill for four to six years. Researchers track heart attacks, cancer, dementia, and death, plus how well people move and function day to day.

Why Regulators Are Paying Attention

What makes TAME unusual is not just its size. It was designed with the Food and Drug Administration at the table from the start. The goal was to create a path toward approving a drug for aging itself, not just for one disease. That would be a first in American medicine, and it explains why the trial has drawn attention far beyond typical diabetes research.

Researchers built TAME around a single idea. Aging is the biggest risk factor for heart disease, cancer, and dementia combined. Instead of testing a drug against one illness, TAME measures whether metformin delays a mix of them showing up at all. Investigators called this approach a way to test whether a drug can help older adults simply function better, longer.

What Earlier Studies Already Found

Before TAME began, smaller studies gave scientists reason to think metformin was worth testing this way. The MILES study looked at whether metformin could shift older adults’ gene activity patterns to resemble those of younger, healthier people. Researchers measured this directly in blood samples from study participants over several months.

A separate biomarkers effort tied to the TAME program pushed this further, working to identify measurable signs in blood and tissue that track biological aging in real time. The idea is that if metformin changes those markers alongside disease outcomes, it strengthens the case that the drug is doing more than managing blood sugar.

Review papers written by aging researchers describe metformin as already showing protective effects against several age-related diseases in humans, based on years of diabetes-related data. That track record is part of why the drug moved from a diabetes shelf to a landmark aging trial in the first place.

The Open Questions Researchers Are Still Answering

One honest limitation shapes how this story should be read. Much of the strongest human evidence so far comes from people who already have diabetes, prediabetes, or insulin resistance, not from healthy older adults with normal blood sugar. Whether the same benefits show up in metabolically healthy people is a separate question TAME and related studies are still working to answer.

Scientists are also mapping out how metformin might interact with the most proven anti-aging tool available: exercise. Researchers are studying whether the drug changes how the body adapts to physical training in older adults, since any interference there would matter for how the drug fits into everyday health routines.

'Wonder Drug': Common Diabetes Pill Could Transform How We Age, Scientists Say | Peter Dockrill, ScienceAlert

A common drug that's been used to treat patients since the 1950s may hold transformative potential for human health, researchers say.

In a new review, scientists go as… pic.twitter.com/PisMroC05u

— Owen Gregorian (@OwenGregorian) September 3, 2026

None of this means older Americans should start taking metformin off-label for anti-aging purposes. TAME’s own investigators built the trial precisely because the aging benefit, while biologically plausible and worth testing at scale, has not yet been proven the way a completed clinical trial proves a treatment works. The trial exists to settle that question with real data, not assumptions.

What sets metformin apart from typical longevity fads is its paper trail. Decades of diabetes prescriptions, a known safety record, and a nine-figure federal research effort back it, unlike most supplements marketed on the promise of slowing aging. Interim signals from the TAME program have already pointed toward reduced rates of several age-related conditions among participants, adding weight to a hypothesis regulators found credible enough to help design a trial around in the first place.